Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.


Estrogen Receptor Alpha (ER) is expressed in about 70% of breast cancer and mediates various cellular signaling events including cell cycle. The antiestrogen tamoxifen is currently administered to patients in order to induce regression of the tumor growth of estrogen receptor positive (ER+) breast cancer. However, upon continued administration, patients… (More)
DOI: 10.1080/15384101.2016.1220460


14 Figures and Tables